In the Sorafenib resistant xenograft model, we tested the effect of 17-AAG combined with Sorafenib and HSP90α knockdown combined with Sorafenib, the results indicated that Sorafenib reduced the tumor growth most significantly when HSP90α was inhibited (Figure 6A–C). Here, HSP90AA1 is linked to neoplasm.